Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest
|
|
- Nathan Stokes
- 6 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2007, p Vol. 45, No /07/$ doi: /jcm Copyright 2007, American Society for Microbiology. All Rights Reserved. Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest Anne Bolmström, 1 Åsa Karlsson, 1 Anette Engelhardt, 1 Phion Ho, 1 Peter J. Petersen, 2 Patricia A. Bradford, 2 and C. Hal Jones 2 * AB BIODISK, Solna, Sweden, 1 and Infectious Diseases Research, Wyeth Research, Pearl River, New York 2 Received 12 January 2007/Returned for modification 22 March 2007/Accepted 11 May 2007 A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n 266) and gram-positive (n 162) aerobic bacteria, a collection of anaerobes (n 385), and selected collections of nonpneumococcal (n 369), Streptococcus pneumoniae (n 372), and Haemophilus influenzae (n 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter- and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method ( 1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination. Sixty years after the development of the first tetracyclines, this class of antibacterial agents is a benchmark in terms of antibacterial spectrum, ease of use, and safety profile (19). Tigecycline, the novel 9-t-butyl substituted minocycline derivative, is the first-in-class glycylcycline. Tigecycline was recently approved worldwide for use in patients with complicated skin and skin structure infections and complicated intra-abdominal infections. The broad spectrum of activity of tigecycline against gram-negative and gram-positive pathogens matched that seen with classical tetracyclines (1, 4, 9, 13). However, in contrast to the classical tetracyclines, tigecycline was not subject to efflux through the tetracycline specific efflux pumps or affected by the ribosomal protection mechanism of tetracycline resistance (11, 14, 18). In addition, tigecycline showed a good profile against important clinical pathogens: methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate resistant S. aureus (and heterogeneous glycopeptide-intermediate resistant S. aureus), vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae, and resistant gram-negative aerobic bacilli producing extended-spectrum -lactamases (4, 12 14, 18). The development and validation of reliable methods for antimicrobial susceptibility testing (AST) and MIC determinations of tigecycline are critical to clinical practice, as well as for ongoing surveillance programs, for this novel agent. Clinical microbiology laboratories have a number of AST methodologies available for daily clinical work. In order to validate and assess the reproducibility of Etest tigecycline (2, 5, 6), a multicenter study was conducted to compare MIC determinations with this method to the Clinical Laboratory Standards Institute (CLSI) reference broth microdilution * Corresponding author. Mailing address: Wyeth Reseaarch, 401 N. Middletown Rd., Bldg. 200, Rm. 3219, Pearl River, NY Phone: (845) Fax: (845) jonesh3@wyeth.com. Published ahead of print on 23 May and agar dilution (AD) assays. Test collections of organisms comprising clinical isolates, as well as strains having a wide range of susceptibilities to tetracyclines, tigecycline, and/or resistance to other antibiotics, were used in the comparative studies. (This study was presented in part previously [A. Bolmström, Å. Karlsson, P. Ho, A. Wanger, and R. Howe, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstr. D-1645, 2005].) MATERIALS AND METHODS Bacteria. An identical set of five bias/precision test organism collections (aerobes, anaerobes, nonpneumococcal, S. pneumoniae, and H. influenzae) were tested once by each of three study sites using Etest. The composition of each group of organisms is detailed in Table 1. Each of the study sites also tested five collections of clinical isolates (aerobes, anaerobes, nonpneumococcal, S. pneumoniae, and H. influenzae); details on each of the five organism groups are presented in Table 2. At least 50% of the strains comprising the clinical collection were defined as fresh clinical isolates, having been on an agar plate for less than 7 days and never frozen. The remainder of the strains could be sourced from existing clinical collections. In addition, study site 1 used five AST challenge collections (aerobes, anaerobes, nonpneumococcal, S. pneumoniae, and H. influenzae) comprising strains from various culture collections with a wide range of susceptibilities to tetracyclines and tigecycline and/or resistance to other antibiotics to specifically evaluate whether Etest tigecycline can reliably detect tigecycline-intermediate and -resistant (nonsusceptible) organisms. The make-up of the AST challenge collections is also detailed in Table 2. Quality control (QC) strains recommended by the CLSI for aerobes, anaerobes, nonpneumococcal, S. pneumoniae, and H. influenzae (Table 3) were used throughout the studies and comprised part of the reproducibility collections. Antimicrobial agents. Tigecycline was provided by Wyeth (Pearl River, NY) and used according to guidelines published by CLSI (7, 8). Etest tigecycline gradient strips (0.016 to 256 g/ml) were provided by AB BIODISK (Solna, Sweden) and used according to the product insert and the manufacturer s instructions. Susceptibility testing. (i) Media. Cation-adjusted Mueller-Hinton II broth (MHB; Becton Dickinson, Sparks, MD) was used for broth microdilution with aerobes and Mueller-Hinton agar (Becton Dickinson) was used for Etest and 2474
2 VOL. 45, 2007 TIGECYCLINE Etest 2475 TABLE 1. Composition of bias/precision bacterial test groups for Etest validation Test group Organism No. of strains tested Aerobes Acinetobacter baumannii 1 Enterobacter agglomerans 1 Enterobacter cloacae 2 Escherichia coli 2 Citrobacter spp. 1 Klebsiella pneumoniae 2 Klebsiella oxytoca 1 Morganella morganii 1 Pseudomonas aeruginosa 1 Serratia spp. 1 Stenotrophomonas maltophilia 1 Enterococcus faecalis 2 Enterococcus faecium 2 Enterococcus gallinarum 1 Staphylococcus aureus 4 a Staphylococcus epidermidis 1 CNS b 2 c Total 26 Nonpneumococcal Streptococcus pyogenes 9 Streptococcus agalactiae 9 Viridans group 8 Total 26 Anaerobes Bacteroides fragilis 9 Bacteroides ovatus 4 Bacteroides thetaiotaomicron 7 Bacteroides vulgatus 6 Total 26 S. pneumoniae 28 H. influenzae 25 Bias/precision collection total a Two methicillin-susceptible S. aureus and two methicillin-resistant S. aureus strains. b CNS, coagulase-negative Staphylococcus spp. c Both isolates were methicillin resistant. AD with aerobes. A total of 5% lysed horse blood was added to MHB for testing S. pneumoniae and Streptococcus spp. with broth microdilution, and 5% laked sheep blood was added to Mueller-Hinton agar for the Etest. Anaerobes were tested with brucella blood agar base (Becton Dickinson) supplemented with 5% laked sheep blood, hemin, and vitamin K (BBA) according to the CLSI guidelines for AD, and the same agar was used for Etest. Haemophilus test medium (prepared in-house or purchased from Remel, Lenexa, KS) was used for both the broth microdilution and the Etest for H. influenzae. (ii) Dilution procedures. Broth microdilution was carried out according to the CLSI guidelines for tigecycline (7). Specifically, in light of the demonstrated oxygen sensitivity of tigecycline (3, 17), MHB used for MIC determinations was prepared fresh ( 12 h old at the time of use). Microdilution plates were prepared on the day of use, and the freshly prepared tigecycline stock solution was serially diluted in fresh MHB to provide a range of 15 twofold doubling dilutions (0.016 to 256 g/ml) to match the Etest concentration gradient range. The MIC was determined as the lowest concentration of tigecycline that inhibited growth as judged by the unaided eye. The AD method for aerobes was performed according to CLSI guidelines (7, 16). (iii) Etest. Etest tigecycline (0.016 to 256 g/ml; AB BIODISK, Solna, Sweden) was used according to the manufacturer s instructions. Briefly, an inoculum suspension with a turbidity equivalent to 0.5 McFarland standard was prepared by suspending well-isolated colonies in 0.9% saline for aerobes and in MHB for nonpneumococcal, S. pneumoniae and H. influenzae. For anaerobes, bacterial suspension in brucella broth with a turbidity equivalent to 1 McFarland was used. A sterile cotton swab dipped into the suspension was used to evenly streak the agar surface and allowed to dry for approximately 15 min. In the case of anaerobes, exposure to ambient air was minimized ( 15 min). The Etest tigecycline gradient strip was applied to the agar surface, and the plate was 131 TABLE 2. Composition of clinical and challenge bacterial test collections for Etest validation Test Group Organism Site (no. of organisms tested) No. of TGC nonsusceptible organisms tested a Aerobes Acinetobacter spp NA b Citrobacter spp E. agglomerans E. cloacae E. coli K. pneumoniae Serratia spp E. faecalis E. faecium S. aureus CNS c Total Nonpneumococcal S. pyogenes S. agalactiae Viridans group S. dysgalactiae Total Anaerobes B. fragilis B. ovatus B. thetaiotaomicron B. vulgatus Bacteroides spp Total S. pneumoniae NA H. influenzae NA Total clinical collections Challenge groups Aerobes Acinetobacter spp. 4 NA Citrobacter spp. 4 E. agglomerans 2 E. cloacae 5 E. coli 5 Klebsiella spp. 10 M. morganii 1 P. stuartii 1 1 P. aeruginosa 2 NA S. maltophilia 3 NA Serratia spp. 2 E. faecalis 4 E. faecium 3 E. gallinarum 1 S. aureus 14 1 S. epidermidis 1 CNS 10 1 Total 72 3 Nonpneumococcal S. pyogenes 25 S. agalactiae 25 Viridans group 21 1 Total 71 1 Anaerobes B. fragilis 36 2 B. ovatus 12 2 B. thetaiotaomicron 17 2 B. vulgatus 10 1 Total 75 7 S. pneumoniae 75 NA H. influenzae 75 NA Total challenge strains Total all strains tested 1, a Includes tigecycline-intermediate and -resistant organisms. b NA, not applicable since breakpoints have not been defined for this organism. c CNS, coagulase-negative Staphylococcus spp.
3 2476 BOLMSTROM ET AL. J. CLIN. MICROBIOL. TABLE 3. Bias and precision of Etest versus broth microdilution Test group No. of EAs per site (%) a Site 1 Site 2 Site 3 incubated in ambient air at 35 C for 18 to 20 h for aerobes; in 5% CO 2 for 20 to 24 h for nonpneumococcal, S. pneumoniae, and H. influenzae; and in an anaerobic chamber for 24 to 48 h for anaerobes. The MIC endpoint was read where the growth inhibition ellipse intersected the MIC on the Etest gradient strip. Whenever different growth inhibition patterns and/or growth trailing were seen, the MIC endpoint of the first point of significant inhibition, as judged by the naked eye, was selected using the reading guidelines and illustrations provided by the manufacturer. QC. The following QC strains, as appropriate, were tested in parallel and on all test occasions for both the reference methods and Etest: S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Eubacterium lentum ATCC Inoculum density checks in terms of CFU/ml for all test procedures were performed with colony count assays for each QC strain and method and all bias/precision tests and for 10% of all clinical isolates for the different organism groups at all three study centers. RESULTS Interlaboratory reproducibility (%) b Aerobes Nonpneumococcal Anaerobes S. pneumoniae H. influenzae Total a Etest readings 1 log 2 dilution of the reference method mode. b Etest readings from all three tests sites 1 log 2 dilution of the Etest mode. QC strains. QC data (60 results) for each of the ATCC QC reference strains for all three study centers were reported to be within the acceptable QC ranges as specified by the CLSI (8). In addition, there was complete agreement between the reference dilution methods and Etest; i.e., 100% of Etest QC results were within acceptable tolerance limits (essential agreement [EA]) limits ( 1 log 2 dilution) of the respective reference method. Bias and precision testing. The interlaboratory variability of Etest performance was assessed by comparing the Etest results for each organism reported by each study site for the groups of organisms in the 5-bias/precision collections (aerobes, anaerobes, nonpneumococcal, S. pneumoniae, and H. influenzae). The bias/precision collections were blinded to all three investigator sites. Interlaboratory reproducibility ( 1 log 2 dilution) was 100% for all five groups of organisms (Table 3). Etest MIC results from each study site were also compared to the mode of the reference result (n 3) for each group of organisms (EA). For the 393 readings taken, the EA was between 88 and 100% for the three study sites. Most of the discrepant readings were for the H. influenzae collection, and when this collection was excluded the EA was 92 to 100% for the three sites (Table 3). Clinical and challenge strains. Comparison of Etest results to reference methodologies for the clinical collections from all three sites plus the AST challenge collections from site 1 is presented in Table 4. The EA was greater than 98% for all five of the organism groups from the three study sites. Eight minor TABLE 4. Comparison of Etest and reference method for tigecycline susceptibility testing of the clinical and stock test collections including challenge strains Test group No. organisms tested No. of EAs (%) a Interpretive category discrepancies (%) b Minor Major Very major Aerobes (99.3) 8 (1.9)* 0 0 Nonpneumococcal (100) Anaerobes (98.2) 12 (3.1)* 0 0 S. pneumoniae (98.9) H. influenzae (98.7) Total 1, (99) 20 (1.0)* 0 0 a Etest result 1 log 2 dilution of the reference method result. b For organisms for which the breakpoints have been approved by the U.S. Food and Drug Administration: aerobes 315 isolates. The EA for isolates marked with an asterisk was 100%. errors occurred with the gram-negative and gram-positive aerobes. In the case of the gram-negative aerobes, the seven minor errors were caused by two K. pneumoniae and five Serratia spp. for which the Etest MIC results were 1 dilution lower than the broth microdilution for four of the seven tests (Fig. 1). The one minor error that occurred with the gram-positive aerobes was caused by S. aureus Mu50 (ATCC ) for which the broth microdilution result was 1 g/ml and the Etest result 0.38 g/ml. Twelve minor errors occurred with the collection of anaerobes studied (Table 4). The minor errors were caused by three B. fragilis, three B. thetaiotaomicron, five B. ovatus, and one B. uniformis strain. Etest MICs were lower than the AD result for 9 of the 12 tests (Fig. 2). In contrast to the data from the bias/precision collection above, when the clinical collection of 372 H. influenzae isolates was tested the EA was found to be 98.7% with no CA errors (Table 4 and Fig. 3). The AST challenge collections, comprising clinical isolates and culture collections that included tigecycline and/or tetracycline-susceptible, -intermediate, and -resistant isolates and strains resistant to other classes of antibiotics, were used to evaluate the ability of Etest to reliably detect tigecycline nonsusceptible isolates. EA between Etest and reference methods for the aerobes in the collection was 99.3% with 1.9% minor errors (Table 4). The aerobes incorrectly categorized by Etest included three Serratia spp. isolates, two of which tested intermediate (MIC 3 g/ml) by Etest and resistant (MIC 8 g/ml) by the reference method, and a third isolate that tested resistant (MIC 8 g/ml) by Etest and intermediate (MIC 4 g/ml) by use of the reference broth. There were also two minor errors with K. pneumoniae isolates; in both cases the isolates tested susceptible (MIC 2 g/ml) by Etest and intermediate (MIC 4 g/ml) by reference method. The final aerobe that was categorized as susceptible by Etest (MIC 0.38 g/ml) and nonsusceptible (MIC 1 g/ml) by broth microdilution was S. aureus Mu50 isolate described above. In the case of the anaerobes in the collection, EA was 98.2%, and there were 3.1% minor errors (Table 4). Five test isolates (two B. thetaiotaomicron, two B. ovatus, and one B. fragilis) resulted in a susceptible interpretation (MIC 4 g/ml) by Etest and
4 VOL. 45, 2007 TIGECYCLINE Etest 2477 FIG. 1. Error rate-bounded analysis comparing tigecycline reference broth dilution with tigecycline Etest strips against 221 gram-negative isolates. The datum points that fall along the diagonal line of the scattergram represent EA between the Etest result (x axis) and the broth microdilution result (y axis). Dotted horizontal and vertical lines demarcate the susceptible ( 2 g/ml), intermediate (4 g/ml), and resistant ( 8 g/ml) categories along both axes. The datum points falling within the quadrant lines represent minor errors. Note that an Etest result that falls between twofold dilutions must be rounded up to the next upper twofold value before categorization. The gram-negative collection includes: Citrobacter spp., Enterobacter cloacae, E. coli, Klebsiella oxytoca, K. pneumoniae, Morganella morganii, Providencia stuartii, and Serratia spp. intermediate (MIC 8 g/ml) by the reference method AD. In addition, four isolates (three B. ovatus and one B. thetaiotaomicron) tested as intermediate (MIC 8 g/ml) by Etest and resistant (MIC 16 g/ml) by AD, whereas a single B. fragilis isolate tested resistant (MIC 12 g/ml) by Etest and intermediate (MIC 8 g/ml) by AD. The remaining three test groups in the AST challenge collection nonpneumococcal, S. pneumoniae, and H. influenzae had EA values of 100, 98.9, and 98.7%, respectively, and resulted in no minor errors (Table 4). FIG. 2. Error rate-bounded analysis comparing tigecycline reference broth dilution with tigecycline Etest strips against 386 anaerobes. The datum points that fall along the diagonal line of the scattergram represent EA between the Etest result (x axis) and the AD result (y axis). Dotted horizontal and vertical lines demarcate the susceptible ( 4 g/ml), intermediate (8 g/ml), and resistant ( 16 g/ml) categories. The datum points falling within the quadrant lines represent minor errors. Note that an Etest result that falls between twofold dilutions must be rounded up to the next upper twofold value before categorization. The anaerobe collection includes: Bacteroides caccae, B. distasonis, B. fragilis, B. ovatus, B. thetaiotaomicron, B. uniformis, B. ureolyticus, B. vulgatus, and other Bacteroides spp.
5 2478 BOLMSTROM ET AL. J. CLIN. MICROBIOL. FIG. 3. Error rate-bounded analysis comparing tigecycline reference broth dilution with tigecycline Etest strips against 374 H. influenzae isolates. The datum points that fall along the diagonal line of the scattergram represent the EA between the Etest result (x axis) and the broth microdilution result (y axis). Horizontal and vertical lines demarcate the hypothetical nonsusceptible MIC (MIC 0.5 g/ml) along both axes. Note that an Etest result that falls between twofold dilutions must be rounded up to the next upper twofold value before categorization. DISCUSSION The importance of a robust, reliable, and simple-to-use AST device for the clinical microbiology laboratory cannot be overstated. This is even more important for the testing of isolates from critical infections and high-risk patients and where dosage considerations are important in targeting therapy. The Etest predefined gradient strip can be set up as easily as a Kirby-Bauer disk diffusion test by most clinical laboratories without the need for specialized equipment. As novel antimicrobial agents become available for clinical use, the commercial availability and performance validations of Etest gradient strips for these agents in comparison to reference methods becomes an essential exercise. The data presented in the present study verify that the tigecycline Etest gradient method was as accurate as the reference methods for all five organism groups tested with excellent EA for the majority of the 1,926 strains tested. In addition, the error rates were very low. These outcomes are well within the target accuracy as suggested by the CLSI (15) and used by the U.S. Food and Drug Administration (10) to assess the substantial equivalence of the performance of alternative methods and products in comparison to reference methods. The ability of Etest tigecycline to reliably detect tigecycline susceptible and resistant isolates was evaluated with a collection of 1926 strains resulting in 1.0% minor errors. It should be noted that EA for the nonsusceptible strains was 100% and the categorical agreement errors are a by-product of clustering at the breakpoints and the inherent tolerance ( 1 dilution) of AST methodologies. U.S. Food and Drug Administration-defined breakpoints were applied in these studies (Wyeth Pharmaceuticals, Tygacil package insert [ /foi/label/2005/021821lbl.pdf]): Staphylococcus (susceptible only breakpoint, 0.5 g/ml), Streptococcus (not including S. pneumoniae) and Enterococcus (susceptible only breakpoint, 0.25 g/ml), Enterobacteriaceae (susceptible, 2 g/ml; intermediate, 4 g/ml; resistant, 8 g/ml), and anaerobes (susceptible, 4 g/ml; intermediate, 8 g/ml; resistant, 16 g/ ml). Hypothetical breakpoints were applied for S. pneumoniae and H. influenzae (susceptible only breakpoint, 0.25 g/ml). In the present study, testing was carried out independently at three test sites using collections of recently acquired clinical isolates and an AST challenge collection, including a representation of tigecycline-nonsusceptible isolates. However, in order to evaluate inter- and intralaboratory reproducibility, each site tested a common bias/precision collection of organisms that was blinded. Etest tigecycline demonstrated excellent reproducibility (100%) of the MIC results when the same 131 isolates were tested across all study sites. Only in the case of the H. influenzae group did two of the sites show less than optimal correlation (88%) with the broth microdilution reference method. Interestingly, in all cases, Etest MIC results were 1 log 2 dilution higher than the reference broth dilution method. The less-than-optimal reproducibility observed with H. influenzae could be attributed among other factors to variability in the quality of the Haemophilus test medium agar and ambient incubation of capnophilic organisms in broth that may influence AST results. It should be noted that for the much larger collection of H. influenzae (372 clinical isolates), the EA was 98.7%, with EA rates of 95.9, 99, and 100% for the three respective sites (Table 4 and Fig. 3). In conclusion, Etest tigecycline gradient strips proved to be robust and reliable even when tested with large collections of diverse organism groups in this multicenter analysis and should provide accurate and reproducible MIC results when used in daily clinical practice. REFERENCES 1. Babinchak, T., E. J. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh The efficacy and safety of tigecycline in the treatment of complicated intra-
6 VOL. 45, 2007 TIGECYCLINE Etest 2479 abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41:S354 S Baker, C. N., S. A. Stocker, D. H. Culver, and C. Thornsberry Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J. Clin. Microbiol. 29: Bradford, P. A., P. J. Petersen, M. Young, C. H. Jones, M. Tischler, and J. O Connell Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49: Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5):S315 S Brown, D. F., and L. Brown Evaluation of the E test, a novel method of quantifying antimicrobial activity. J. Antimicrob. Chemother. 27: Citron, D. M., M. I. Ostovari, A. Karlsson, and E. J. Goldstein Evaluation of the E test for susceptibility testing of anaerobic bacteria. J. Clin. Microbiol. 29: CLSI Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA. 8. CLSI Performance standards for antimicrobial susceptibility testing: M100-S16, 16th informational supplement. CLSI, Wayne, PA. 9. Ellis-Grosse, E., T. Babinchak, N. Dartois, G. Rose, and E. Loh The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin/aztreonam. Clin. Infect. Dis. 41:S341 S Food and Drug Administration Class II special controls guidance document: antimicrobial susceptibility test systems (AST) guidance for industry. U.S. Food and Drug Administration, Washington, DC. [Online.] Hirata, T., A. Saito, K. Nishino, N. Tamura, and A. Yamaguchi Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob. Agents Chemother. 48: Hoban, D., S. Bouchillon, B. Johnson, J. Johnson, and M. Dowzicky In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. 52: Jones, C. H., and P. J. Petersen Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today 41: Jones, C. H., M. Tuckman, A. Y. Howe, M. Orlowski, S. Mullen, K. Chan, and P. A. Bradford Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob. Agents Chemother. 50: NCCLS Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2, 2nd ed., vol. 18. National Committee for Clinical Laboratory Standards, Villanova, PA. 16. NCCLS Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6, 6th ed., vol. 24. National Committee for Clinical Laboratory Standards, Wayne, PA. 17. Petersen, P. J., and P. A. Bradford Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49: Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43: Roberts, M. C Tetracycline therapy: update. Clin. Infect. Dis. 36: Downloaded from on July 10, 2017 by guest
Guidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel
Guidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes
More informationAbstract. Mary Jane Ferraro, PhD, MPH Jana M. Swenson, MMSc
January 2009 Vol. 29 No. 2 Replaces M07-A7 Vol. 26 No. 2 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Eighth Edition This document addresses
More informationDetermination of Penicillin MICs for Streptococcus pneumoniae by Using a Two- or Three-Disk Diffusion Procedure
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 179 183 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Determination of Penicillin MICs for Streptococcus pneumoniae
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationEM021. Co-Trimoxazole Ezy MIC TM Strip (COT)( mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing
Co-Trimoxazole Ezy MIC TM Strip (COT)(0.002-32 mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing For In Vitro Diagnostic use EM021 Not for Medicinal Use It is a unique MIC
More informationAntimicrobial susceptibility testing. EUCAST disk diffusion method
Antimicrobial susceptibility testing EUCAST disk diffusion method Version 2.1 February 2012 Contents Page Abbreviations and Terminology 1 Introduction 4 2 Preparation of media 5 3 Preparation of inoculum
More informationValidation of the Automated Reading and Incubation System with Sensititre Plates for Antimicrobial Susceptibility Testing
JOURNAL OF CLINICAL MICROBIOLOGY, May 2003, p. 1951 1956 Vol. 41, No. 5 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.5.1951 1956.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationEzy MIC Strip FEATURES AND ADVANTAGES
Imipenem with & without EDTA Ezy MIC Strips (IPM+EDTA/IPM) (Imipenem + EDTA: 1-64 mcg/ml) (Imipenem : 4-256 mcg/ml) Antimicrobial Susceptibility Testing For In Vitro Diagnostic use EM078 Not for Medicinal
More informationAntimicrobial Susceptibility Testing
AST Antimicrobial Susceptibility Testing Marc V. Assous, MD, PhD Shaare Zedek Med. Ctr. Universite Paris Descartes The purpose To present the methods used for AST A - Micro-dilution (ISO 20776-2006) B
More informationANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED
ANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED Romney Humphries, Ph.D., DABMM Section Chief, Clinical Microbiology University of California Los Angeles Lost Angeles, CA Susan E. Sharp, Ph.D., DABMM, FAAM
More informationMeropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group
Journal of Antimicrobial Chemotherapy (99) 7, 599-606 Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group J. A. Garcia-Rodriguez, J. E. Garcia Sanchez,
More informationReport on New Patented Drugs - Invanz
Report on New Patented Drugs - Invanz October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationChapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method)
Chapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method) The disk diffusion method presented in this chapter has been carefully standardized by the National Committee for Clinical Laboratory
More informationNCCLS Standards for Antimicrobial Susceptibility Tests
CE Update Microbiology III NCCLS Standards for Antimicrobial Susceptibility Tests Clyde Thornsberry, PhD T he most requested test of the clinical microbiology laboratory today is probably t h e antimicrobial
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationTesting: Evaluation of Overnight Agar Cultures and the Rapid Inoculum Standardization System
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1983, p. 45-457 95-1137/83/345-8$2./ Copyright 1983, American Society for Microbiology Vol. 17, No. 3 Inoculum Standardization in Antimicrobial Susceptibility Testing:
More informationEvaluation of a Rapid Bauer-Kirby Antibiotic Susceptibility
ANTIMICROBIAL AGENTS AND CHEMoTHERAPY, Mar. 1975. p. 250-255 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 3 Printed in USA. Evaluation of a Rapid Bauer-Kirby Antibiotic Susceptibility
More informationABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18
M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,
More informationIn Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 943 949 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vivo Pharmacodynamic Activities
More informationDevelopment of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories
ORIGINAL ARTICLE BACTERIOLOGY Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories E. Matuschek 1, D. F. J. Brown
More informationBD BBL CHROMagar CPE
INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA BD BBL CHROMagar CPE PA- 257681.02 Rev. January 2017 INTENDED USE BD BBL CHROMagar CPE is a selective chromogenic screening medium for the detection of carbapenemase
More informationSupplementary Information for
Supplementary Information for Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis J. Choi 1, H. Y. Jeong 2,3, G. Y. Lee 2,4, S. Han 1, S.
More informationM. Ben-David 1, O. Hammer 1, A.Scinderman 1, Y. Gluckman-Yavo 1, M. Fridman 1, D. Gohman 1, G. Ingber 1 and E. Zahavy 2
441 Rapid Gram Negative Antimicrobial Susceptibility Testing Directly from Positive Blood Culture based on a Unique Spectral Intensity Ratio Analysis via Single Fluorescence Membrane Dye Staining and Flow
More informationCONTROL OF MICROBIAL GROWTH - DISINFECTANTS AND ANTISEPTICS
CONTROL OF MICROBIAL GROWTH - DISINFECTANTS AND ANTISEPTICS Specific control measures can be used to kill or inhibit the growth of microorganisms. A procedure which leads to the death of cells is broadly
More information6/21/2012 Speaker Hannah Wexler, PhD, Objectives Continuing Education Credit program and evaluation by 07/21/ an Archived Program 612an
Anaerobic Bacteria Susceptibility Testing 6/21/2012 Speaker Hannah Wexler, PhD, Adjunct Professor, Department of Medicine UCLA School of Medicine, Los Angeles, CA Dr. Hannah Wexler is an Adjunct Professor
More informationAntibiotic Susceptibility Testing. Part I
CE Update Microbiology I Antibiotic Susceptibility Testing. Part I Patrick R. Murray, PhD W ith the introduction of antimicrobial c h e m o t h e r a p y in t h e 1940s, the hope of eliminating infectious
More informationTest Method for Efficacy of Copper Alloy Surfaces as a Sanitizer
Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa (ATCC 15442) Methicillin Resistant
More informationBacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections
Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections November 7, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking statements that involve risks,
More informationSusceptibility Testing
APPLTE MICROBIOLOGY, Feb. 1970, p. 259-263 Copyright 1970 American Society for Microbiology Vol. 19, No. 2 Printed in U.S.A. In Vitro Antibacterial Activity of Minocycline and Effect of Agar Medium Utilized
More informationEffect of Storage of Mueller-Hinton Agar Plates on
APPUED MICROBIOLOGY, Sept. 1970, p. 293-297 Copyright 1970 American Society for Microbiology Vol. 20, No. 3 Printed in U.S.A. Effect of Storage of Mueller-Hinton Agar Plates on Zone Sizes for Antimicrobial
More informationF or many years, the isolation of urinary pathogens has
608 ORIGINAL ARTICLE A comparison of the performance of commercially available chromogenic agars for the isolation and presumptive identification of organisms from urine D Fallon, G Ackland, N Andrews,
More informationPolymicrobial Infection in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1531-1535 0066-4804/93/071531-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 7 Use of Cephalosporins for Prophylaxis and
More informationBD Mueller Hinton Chocolate Agar
PA-254035.05-1 - INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA PA-254035.05 Rev.: Sep 2011 BD Mueller Hinton Chocolate Agar INTENDED USE BD Mueller Hinton Chocolate Agar is used for the isolation and
More informationBiofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
More informationMicroorganisms in Blood Cultures
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 980, p. 8-8 009-37/80/03-08/0$0.00/0 Vol., No. 3 Evaluation of Acridine Orange Stain for Detection of Microorganisms in Blood Cultures L. R. McCARTHY* AND J. E. SENNE
More informationEvaluation of Use of a New Chromogenic Agar in Detection of Urinary Tract Pathogens
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1998, p. 990 994 Vol. 36, No. 4 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Evaluation of Use of a New Chromogenic Agar in Detection of
More informationBD Columbia CNA Agar with 5% Sheep Blood, Improved II
INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA PA-257303.04 Rev.: Sep 2011 BD Columbia CNA Agar with 5% Sheep Blood, Improved II INTENDED USE BD Columbia CNA Agar with 5% Sheep Blood, Improved II is a
More informationBacterial Contamination in Platelets Canadian Blood Services - Update. Sandra Ramirez-Arcos ISBT TTID WP Meeting June 17, 2017
Bacterial Contamination in Platelets Canadian Blood Services - Update Sandra Ramirez-Arcos ISBT TTID WP Meeting June 17, 2017 Bacterial testing automated BacT/ALERT 3D culture system Routine Platelet Screening
More informationProject 5: Urine Cultures and Identification
Project 5: Urine Cultures and Identification Readings: http://www.webmd.com/a-to-z-guides/urine-culture http://www.medscape.com/viewarticle/558845 (Listen to the two lectures by Dr. Robert A. Weinstein.)
More informationShionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S ), a Siderophore Cephalosporin
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin Osaka, Japan, April 22, 2017 - Shionogi & Co., Ltd. today announced
More informationCONTROL OF MICROBIAL GROWTH - DISINFECTANTS AND ANTISEPTICS
CONTROL OF MICROBIAL GROWTH - DISINFECTANTS AND ANTISEPTICS Specific control measures can be used to kill or inhibit the growth of microorganisms. A procedure which leads to the death of cells is broadly
More informationAntimicrobial Susceptibility Test:
Antimicrobial Susceptibility Test: Product Description is utilized for bacteria and Fungi viability determination. This kit contains WST-8 and electron mediator. WST-8(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,
More informationBD GeneOhm MRSA ACP Lysis Kit
REF 441638 100 Tests DOPS09-09-V1E1 USA Date: 2010-01 TABLE OF CONTENTS INTENDED USE...3 SUMMARY AND EXPLANATION OF THE PROCEDURE...3 REAGENTS...3 PRECAUTIONS...3 MATERIALS PROVIDED...4 STORAGE, HANDLING
More informationThis document is a preview generated by EVS
TECHNICAL SPECIFICATION ISO/TS 16782 First edition 2016-10-15 Clinical laboratory testing Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing
More informationStudy Title Antimicrobial Activity and Efficacy of Seal Shield's Electroclave. Test Method Custom Device Study. Study Identification Number NG7233
Study Title Antimicrobial Activity and Efficacy of Seal Shield's Electroclave Test Method Custom Device Study Study Identification Number NG7233 Study Sponsor Christian Davis Seal Shield 3105 Riverside
More informationInternational Journal of Pharma and Bio Sciences STUDIES ON EFFECT OF CEFOTAXIME AND TERMINALIA CHEBULA ON ESCHERICHIA COLI ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 STUDIES ON EFFECT OF CEFOTAXIME AND TERMINALIA CHEBULA ON ESCHERICHIA COLI ALPA RABADIA *, S.D. KAMAT AND D.V.
More informationOptimized Pathogen Detection with 30- Compared to 20-Milliliter Blood Culture Draws
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2011, p. 4047 4051 Vol. 49, No. 12 0095-1137/11/$12.00 doi:10.1128/jcm.01314-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Optimized
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationChromogenic Culture Media
Color is my day-long obsession, joy, and torment. - Claude Monet Chromogenic Culture Media A Culture of Service Contents BluEcoli CRE Candida ECC E. coli O157 ESBL HUrBi Listeria MRSA SS (Salmonella Shigella)
More informationBacteriology Questionnaire
NEW YORK STATE DEPARTMENT OF HEALTH Wadsworth Center- Clinical Laboratory Evaluation Program P.O. Box 509 Albany, NY 12201-0509 Bacteriology Questionnaire Please complete the sections below. The test services
More informationComparison and Evaluation of Carbenicillin Disks in Diffusion Susceptibility Testing
ANTIMICROBiAL AGENTS AND CHEMOTHERAPY, June 1974, p. 599-606 Copyright 0 1974 American Society for Microbiology Vol. 5, No. 6 Printed in U.S.A. Comparison and Evaluation of Carbenicillin Disks in Diffusion
More informationPostantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae
Journal of Antimicrobial Chemotherapy (1987) 20, Suppl. B, 39-46 Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae
More informationHuman pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
Journal of Antimicrobial Chemotherapy (2005) 55, Suppl. S2, ii25 ii30 doi:10.1093/jac/dki008 JAC Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
More informationAntimicrobial Drugs. Antimicrobial Drugs. The dawn of antibiotics. Alexander Fleming. Chain and Florey. Antibiotics
Antimicrobial Drugs Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease Antimicrobial drugs: Interfere with the growth of microbes within a host Antibiotic: Substance produced by a microbe
More informationDisk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole
J Microbiol Immunol Infect. 2009;42:148-153 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole Sai-Cheong
More informationSimplified Method for Antimicrobial Susceptibility Testing of Anaerobic Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, OCt. 1975, p. 444-452 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 4 Printed in U.S.A. Simplified Method for Antimicrobial Susceptibility Testing
More informationINTRODUCTION Sanitization sterilization Antibiotics Bactericidal Bacteriostatic Antiseptics disinfectants
INTRODUCTION Infectious agents on environmental surfaces, given the correct circumstances, may potentially find their way into an unsuspecting victim. Thus, it is important to keep the surfaces we regularly
More informationTransmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2002, p. 2679 2683 Vol. 46, No. 8 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.8.2679 2683.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationRapid Bacterial Identification Using a Mass Spectrometry Based Molecular Diagnostics Approach: Evaluation of the Iridica Platform
Rapid Bacterial Identification Using a Mass Spectrometry Based Molecular Diagnostics Approach: Evaluation of the Iridica Platform Alec Saitman, PhD, Jane Y. Yang PhD, Sharon Reed, David Pride, Michele
More informationBBL QualiSwab Quality Control Culture Devices
Revisions Rev from Rev to ECO # 0299 0704 2996-04 SO 0191-5 Notes: 1. BD Cat. Number Various 2. Blank (Sheet) Size : Length: 11 Width: 8.5 Number of Pages: 4 Number of Sheets: 1 Page Size: Length 8.5 Width
More informationStandard Operating Procedure
Subject Vitek 2 Compact Identification and Susceptibility Testing Index Number Lab-1512 Section Laboratory Subsection Regional Clinic / Affiliate Hospital Laboratories Category Departmental Contact Sanders,
More informationJundishapur J Microbiol. 2012;5(1): Jundishapur Journal of. Journal home page:
KOWSAR. Jundishapur Journal of Microbiology Journal home page: www.jjmicrobiol.com A Method for Antibiotic Susceptibility Testing: Applicable and Accurate Ramezan Ali Ataee 1, 2, Ali Mehrabi-Tavana 2,
More informationStudy Title Antibacterial Efficacy of Bio-Care Technology's Non-Porous Test Substance
Study Title Antibacterial Efficacy of Bio-Care Technology's Non-Porous Test Substance Test Method Japanese Industrial Standard Z 2801 Antibacterial Products Test for Antibacterial Activity and Efficacy
More informationIAI INTRA-ABDOMINAL INFECTION APPLICATION
IAI INTRA-ABDOMINAL INFECTION APPLICATION Investigational Use. Not available for Sale in the United States. Content UNYVERO IAI APPLICATION The Unyvero IAI Application is a high-quality tool to detect
More informationProject 7: Wound Cultures and Identification
Project 7: Wound Cultures and Identification Readings: https://labtestsonline.org/understanding/analytes/wound-culture/tab/test Identification of Gram-Positive & Gram-Negative Bacteria Guide to laboratory
More informationMicrobiological Quality Control as Described in the Compendia. Scott Sutton, Ph.D.
Microbiological Quality Control as Described in the Compendia Scott Sutton, Ph.D. Microbiological Quality Control as Described in the Compendia Antimicrobial Effectiveness Test , ,
More informationNDA Requirements: Surveillance, Clinical Trial Data, Breakpoints
NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of
More informationCarbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing Fred C. Tenover,* Rajinder K. Kalsi, Portia P. Williams, Roberta B. Carey,* Sheila Stocker,* David Lonsway,*
More informationIntroduction. Abstract. Journal of Scientific and Innovative Research 2014; 3 (1): Available online at:
Journal of Scientific and Innovative Research 214; 3 (1): 43-48 Available online at: www.jsirjournal.com Research Article ISSN 232-4818 JSIR 214; 3(1): 43-48 214, All rights reserved Received: 19-11-213
More informationBD Mac Conkey II Agar / Columbia CNA Agar with 5% Sheep Blood (Biplate)
PA-254447.02-1 - INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA PA-254447.02 Rev.: Sep 2011 BD Mac Conkey II Agar / Columbia CNA Agar with 5% Sheep Blood (Biplate) INTENDED USE BD Mac Conkey II Agar /
More informationRenaissance of the Goldstandard
Renaissance of the Goldstandard (?) Fluorogenic Enzyme Substrates in the Detection and Identification of Bacteria Linda Varadi CSIRO Manufacturing linda.varadi@csiro.au Contact Prof Paul Groundwater Faculty
More informationDeveloping Bacteriophage Therapies for Patients with Antibiotic-Resistant Infections
Developing Bacteriophage Therapies for Patients with Antibiotic-Resistant Infections 2017 BIO International Convention June 21, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking
More informationDepartment of Clinical Microbiology, Statens Serum Institut, Copenhagen, Denmark
ORIGINAL ARTICLE Direct identification and susceptibility testing of enteric bacilli from positive blood cultures using VITEK (GNIþ/GNS-GA) D. S. Hansen, A. G. Jensen, N. Nørskov-Lauritsen, R. Skov and
More informationSeptic Reactions from Apheresis Platelets What have we learned from 10 years of hemovigilance?
Septic Reactions from Apheresis Platelets What have we learned from 10 years of hemovigilance? Anne Eder, MD PhD Adjunct Associate Professor Georgetown University School of Medicine Chief, Blood Services
More informationTable of Contents. A Culture of Service
102714tr Table of Contents 1 BlueEcoli 2 Candida 3 CRE 4 ECC 5 HurBi 6 ESBL 7 Listeria 8 MRSA 9 O157 10 Sakazakii 11 Salmonella 12 SS 13 Staph aureus 14 UTI 15 Vibrio Headquarters A Culture of Service
More informationIn Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2009, p. 3003 3009 Vol. 53, No. 7 0066-4804/09/$08.00 0 doi:10.1128/aac.01584-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. In Vivo
More information55 Industrial Park Road Boothbay, ME USA
Introduction Increasing the level of sanitation and sterility of health-care environments is critical in reducing the transmission of health-care associated infections. The Center for Disease Control estimates
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationAbstract. Introduction
ORIGINAL ARTICLE BACTERIOLOGY A sensitive and specific phenotypic assay for detection of metallo-blactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic
More informationImplementation of the 21 st Century Cures Act for Breakpoints and Interpretive Categories. June 2, 2018 San Diego, California, USA
Implementation of the 21 st Century Cures Act for Breakpoints and Interpretive Categories June 2, 2018 San Diego, California, USA Full Sized Handouts Can Be Found Online at: clsi.org/micro Implementation
More informationQUALITY CONTROL FOR AST: IQCP? Romney Humphries UCLA
QUALITY CONTROL FOR AST: IQCP? Romney Humphries UCLA WHAT IS QUALITY CONTROL? Procedures used to detect errors that occur due to: test system failure adverse environmental conditions variance in operator
More informationPRESERVATIVE EFFICACY TEST FOR COSMETIC PRODUCT
1 SCOPE AND FIELD OF APPLICATION To determine the efficacy of the antimicrobial activity of preservatives used in cosmetic products. The method covers the determination of the suitability of preservation
More informationBIOSAFETY GUIDELINES BACKGROUND ON BIOSAFETY
BIOSAFETY GUIDELINES BACKGROUND ON BIOSAFETY In addition to following general laboratory safety rules, additional rules must be implemented in the microbiology lab since students are working with living
More informationESCMID Online Lecture Library. by author
Eric DANNAOUI ESCMID Postgraduate Education Course 20-22 June 2013, Sibiu Antifungal susceptibility testing and detection of resistance: principles and practices Unité de Parasitologie-Mycologie, Laboratoire
More informationThe Pharmacokinetic and Pharmacodynamic Profile of Tigecycline
SUPPLEMENT ARTICLE The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline Alison K. Meagher, 1,a Paul G. Ambrose, 2 Thaddeus H. Grasela, 1 and Evelyn J. Ellis-Grosse 3 1 Cognigen Corporation, Buffalo,
More informationPharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2006, p. 243 249 Vol. 50, No. 1 0066-4804/06/$08.00 0 doi:10.1128/aac.50.1.243 249.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationUrine Monovette with Boric Acid
with Boric Acid Simulated use - Study showing stabilization of specific microorganisms in urine prepared by: Aktiengesellschaft & Co. SARSTEDT AG & Co. P.O. Box 1220 D-51582 Nümbrecht Phone (+49) 0 22
More informationEvaluation of Antibacterial Activity of Some Medicinal Plants Used in Sudanese Traditional Medicine for Treatment of Wound Infections
Academic Journal of Plant Sciences 2 (4): 246-251, 2009 ISSN 1995-8986 IDOSI Publications, 2009 Evaluation of Antibacterial Activity of Some Medicinal Plants Used in Sudanese Traditional Medicine for Treatment
More informationCombatting AMR: diagnostics
Combatting AMR: diagnostics Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Gonorrhoea: a paradigm for better diagnostics International
More informationEstablishing a Pseudomonas aeruginosa Biofilm in a Murine Model
University of North Texas Health Science Center UNTHSC Scholarly Repository Theses and Dissertations Spring 5-2010 Establishing a Pseudomonas aeruginosa Biofilm in a Murine Model David Valtierra University
More informationNworu & Esimone. Division of Pharmaceutical Microbiology, Department of Pharmaceutics, University of Nigeria, Nsukka, , Enugu State
Research Article Nworu & Esimone Tropical Journal of Pharmaceutical Research, December 2006; 5 (2): 605-611 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights
More informationValidation of antibiotic susceptibility testing guidelines in a routine clinical
AAC Accepts, published online ahead of print on 28 April 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02489-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 Validation
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2001, p. 983 989 Vol. 39, No. 3 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.3.983 989.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Controlled
More informationDetermination of Pseudomonas aeruginosa by Biochemical Test Methods Test, a Modified Biochemical Test for
Japan. J. Microbiol. Vol. 14 (4), 279-284, 1970 Determination of Pseudomonas aeruginosa II. Acylamidase by Biochemical Test Methods the Identification Test, a Modified Biochemical Test for of Pseudomonas
More informationIndigo-Clean White Paper: #1 Bactericidal Performance Testing of Indigo-Clean Upon Bacterial Species. Healthcare
Indigo-Clean White Paper: #1 Bactericidal Performance Testing of Indigo-Clean Upon Bacterial Species Healthcare HC Bactericidal Performance Testing of Indigo-Clean Upon Bacterial Species Clifford J. Yahnke,
More informationDEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 MICROBIOLOGY COMPETENCY EVALUATION FORM STUDENT NAME:
More informationAntimicrobial Susceptibility Testing TECHNICAL SERIES. Practical Issues. ...Setting trends
TECHNICAL SERIES Antimicrobial Susceptibility Testing Practical Issues...Setting trends Other Technical Series Published by TULIP Group 1. Monitoring oral anticoagulant therapy - Concepts & Practice. 2.
More information